Page 29 - Haematologica Vol. 110 - January 2025

EDITORIAL M.R. Litzow
Figure 1. Overall survival of the entire population.1 RL-LAL1913: real-life data on Campus ALL network patients treated according to the LAL1913 protocol. LAL1913: data from the GIMEMA LAL1913 trial; OS: overall survival.
to 4 cycles of consolidation chemotherapy and compared the outcome of this regimen to patients who received the 4 cycles of consolidation chemotherapy alone. The trial demonstrated a 3-year OS of 85% for the blinatumomab + chemotherapy group compared to 68% for the chemo- therapy group alone (P=0.002).8 These results led the FDA to approve blinatumomab for a new indication of use in consolidation treatment. The use of agents like blinatum- omab and inotuzumab ozogamicin, and possibly chimeric antigen receptor T-cell (CAR-T) therapy in the front-line setting, have the potential of not only improving response rates, but also allowing reduced use of chemotherapy with the potential to lessen toxicity and improve outcomes and
References
1. Lazzarotto D, Cerrano M, Papayannidis C, et al. Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study. Haematologica. 2025;110(1):55-67.
2. Bassan R, Chiaretti S, Starza I, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023;7(16):4448-4461.
3. Bouzalmate-Hajjaj A, Massó Guijarro P, Khan K, et al. Benefits of participation in clinical trials: an umbrella review. Int J Environ Res Public Health. 2022;19:1-11.
4. Khosla S, White R, Medina J, et al. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? F1000Res. 2018;7:111-124.
quality of life for patients. It also raises the hope that we can shorten the duration of the long course of chemother- apy that patients with ALL currently endure. The Campus ALL network study shows that excellent outcomes in ALL can be achieved outside the realm of a clinical trial and complements, though does not lessen, the importance of conducting clinical trials to bring further advances to the encouraging improvements we have seen in ALL therapy in recent years.
Disclosures
MRL reports research support and Speaker’s Bureau from Amgen.
5. Concato J, Corrigan-Curay J. Real-world evidence - where are we now? N Engl J Med. 2022;386(18):1680-1682.
6. Jabbour E, Short N, Jain N, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome- negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878-e885.
7. Stelljes M, Raffel S, Alakel M, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome–negative B-precursor ALL. J Clin Oncol. 2023;42(3):273-282.
8. Litzow M, Sun Z, Mattison R, et al. Blinatumomab for MRD- negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024:391(4):320-333.
Haematologica | 110 January 2025
21